Modern treatment of type 2 diabetes mellitus – SGLT2 inhibitors in focus as the “new abc” drugs for diabetes
Abstract
A paradigm shift has happened in the treatment of type 2 diabetes mellitus recently, that is well reflected in the latest domestic and international guidelines. This novel “CRM (cardio-renal-metabolic) approach” advocates for the early introduction of antidiabetic drugs not only for the glycaemic effects but for cardiac and renal benefits. These drugs include SGLT2 inhibitors that showed “CRM” benefits irrespective of the presence of diabetes in several clinical trials. In addition to their glucose lowering effect, SGLT2 inhibitors present physiological properties that could positively influence the course of the “CRM” diseases. These properties translate to clinical evidence that positions them as first-line treatment for heart failure and chronic kidney disease making them effective elements of the therapeutic palette of cardiologists and nephrologists. Based on the above, the currently accepted, individually tailored treatment strategy for type 2 diabetes should focus on the holistic “CRM approach” – the „new ABC” of diabetes care. Along these lines, early introduction of SGLT2 inhibitors as a part of diabetes management is recommended based on hard evidence of their glycaemic efficacy and long-term “CRM” benefits.
References
Egészségügyi szakmai irányelv: A diabetes mellitus kórismézéséről, a cukorbetegek antihyperglykaemias kezeléséről es gondozásáról felnőttkorban. Egészségügyi Közlöny 2023; 73 (13): 1137-1246 / Diabetologia Hungarica 2023; 31: 331-444. https://doi.org/10.24121/dh.2023.20
Központi Statisztikai Hivatal (KSH): 1.17. Krónikus betegségek előfordulási aránya az összlakosság arányában. https://ksh.hu [internet]. https://ksh.hu/s/kiadvanyok/fenntarthato-fejlodes-indikatorai-2023/1-17
Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes [internet]. https://www.who.int/news-room/fact-sheets/detail/diabetes
Chatzis DG, Kolokathis K, Magounoki K és mtsai: Changing the Concept: from the traditional glucose-centric to the new Cardiorenal-metabolic Approach for the treatment of type 2 diabetes. Touchrev in Endocrinol 2021; 17: 92-101. https://doi.org/10.17925/EE.2021.17.2.92
Lingvay I, Sumithran P, Cohen RV és mtsai: Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2022; 399: 394-405. https://doi.org/10.1016/S0140-6736(21)01919-X
Davies MJ, Aroda VR, Collins BS és mtsai: Management of Hyperglycemia in type 2 diabetes, 2022. A Consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45: 2753-2786. https://doi.org/10.2337/dci22-0034
Cosentino F, Grant PJ, Aboyans V és mtsai: 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323. https://academic.oup.com/eurheartj/article/41/2/255/5556890?login=true
Mosenzon O, Del Prato S, Schechter M és mtsai: From glucose lowering agents to disease / diabetes modifying drugs: a "simPle" approach for the treatment of type 2 diabetes. Cardiovascular Diabetology 2021; 20: 92. https://doi.org/10.1186/s12933-021-01281-y
American Diabetes Association Professional Practice Committee, standards of Care in diabetes - 2025. Diabetes Care 2024; 48: 14-336. https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of-Care-in-Diabetes
Marx N, Federici M, Schütt K és mtsai: 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043-4140. https://academic.oup.com/eurheartj/article/44/39/4043/7238227?login=true
Kovács T, Wittmann I: Az SGLT-2-gátló empaglifloznin a diabeteses nephropathia korszerű kezelésében. Diabetologia Hungarica 2017; 25: 241-245. https://doi.org/10.24121/dh.2017.19
Szekeres Zs, Tóth K, Szabados E: The effects of SGLT2 inhibitors on lipid metabolism. Metabolites 2021; 11: 87. https://doi.org/10.3390/metabo11020087
Jermendy Gy: SGLT2-gátlók - diabetologián túlmutató előnyokkel rendelkező antihtyperglykaemiás szerek. Cardiologia Hungarica 2021; 51: 39-48. https://doi.org/10.26430/CHUNGARICA.2021.51.1.39
Benczúr B: Kinek a kezébe valók az SGLT2-gátlók? - Szerkesztőségi állásfoglalás. Az SGLT2-gátlók haszna: túl a glykaemiás hatáson című közleményhez. LAM 2021; 31: 86-88. https://doi.org/10.33616/lam.31.005
Pawlos A, Broncel M, Ewelina W és mtsai: Neuroprotective effect of sglt2 inhibitors. Molecules 2021; 26: 7213. https://doi.org/10.3390/molecules26237213
Nguyen TT, Hoai Ta QT, Nguyen TKO és mtsai: Type 3 diabetes and its role implications in Alzheimer's disease. Int J Mol Sci 2020; 21: 3165. https://doi.org/10.3390/ijms21093165
Molnár GA, Sélley E, Wittmann I: SGTL-2-gátló kezelés diabeteses és nem diabeteses vesebetegségben. Diabetologia Hungarica 2021; 13: 151-160. https://doi.org/10.24121/dh.2021.14
Claggett B, Lachin JM, Hantel S és mtsai: Long-term Benefit of empagliflozin on life expectancy in Patients with type 2 diabetes mellitus and established Cardiovascular disease: Survival estimates from the emPA-reg outCome trial. Circulation 2018; 138: 1599-1601. https://doi.org/10.1161/CIRCULATIONAHA.118.033810
Htoo PT, Tesfaye H, Schneeweiss S és mtsai: Cardiorenal effectiveness of mpagliflozin vs. Glucagon-like peptide-1 receptor agonists: final-year results from the emPrise study. Cardiovasc Diabetol 2024; 23: 57. https://doi.org/10.1186/s12933-024-02150-0
Butler J, Packer M, Filippatos G és mtsai: Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart j 2022; 43: 416-426. https://doi.org/10.1093/eurheartj/ehab798
Hallow KM, Helmlinger G, Greasley PJ és mtsai: Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 2018; 20: 479-487. https://doi.org/10.1111/dom.13126
Proietti R, Rivera-Caravaca JM, López-Gálvez R és mtsai: Cerebrovascular, Cognitive and Cardiac Benefits of SGTL2 inhibitors therapy in Patients with Atrial fibrillation and type 2 diabetes mellitus: Results from a global federated Health network Analysis. J Clin Med 2023; 12: 2814. https://doi.org/10.3390/jcm12082814
Mancia G, Kreutz R, Brunström M és mtsai: 2023 ESH guidelines for the management of arterial hypertension. J Hypertens 2023; 41: 1874-2071. https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx
Fernández-Fernandez B, Sarafidis P, Soler MJ és mtsai: EMPA-KIDNEY: Expanding the range of kidney protection by sglt2 inhibitors. Clin Kidney J 2023; 16: 1187-1198. https://doi.org/10.1093/ckj/sfad082
A Belügyminisztérium egészségügyi szakmai irányelve a felnőttkori idült vesebetegség diagnózisáról es kezeléséről. Hypertonia és Nephrologia 2025; 29: 1-48. Azonosító: 002309. https://jogkodex.hu/doc/4213067
Bailey CJ, Day C, Bellary S: Renal Protection with SGLT2 inhibitors: effects in Acute and Chronic kidney disease. Curr Diab Rep 2022; 22: 39-52. https://doi.org/10.1007/s11892-021-01442-z
Rossing P, Inzucchi SE, Vart P és mtsai: Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the dAPA-Ckd and dAPA-Hf trials. Lancet Diabetes Endocrinol 2022; 10: 24-34. https://doi.org/10.1016/S2213-8587(21)00295-3
Patoulias D, Michailidis T: SGLT-2 inhibitor and GLP-1 receptor Agonist treatment for Patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: is their Combination the optimal treatment option? j Clin transl Hepatol 2022; 10: 574-576. https://doi.org/10.14218/JCTH.2022.00278
Theodorakis N, Nikolaou M: From Cardiovascular-kidneymetabolic syndrome to Cardiovascular-renal-Hepatic-metabolic syndrome: Proposing an expanded framework. Biomolecules 2025; 15: 213. https://doi.org/10.3390/biom15020213
Pereira MJ, Eriksson JW: Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 2019; 79: 219-230. https://doi.org/10.1007/s40265-019-1057-0
Copyright (c) 2026 Szerzők
This work is licensed under a Creative Commons Attribution 4.0 International License.
